SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome
暂无分享,去创建一个
Lin He | Jian Chen | Qinghe Xing | Heng Luo | Lun Yang | Heng Luo | Lun Yang | Lin He | Jing Chen | Q. Xing | Qinghe Xing
[1] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[2] Martine Bagot,et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. , 2002, The Journal of investigative dermatology.
[3] C. Furberg,et al. Adverse cardiovascular effects of rofecoxib. , 2006, The New England journal of medicine.
[4] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[5] Yi Wang,et al. DITOP: drug-induced toxicity related protein database , 2007, Bioinform..
[6] W. Pichler,et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. , 2001, International immunology.
[7] The UniProt Consortium,et al. The Universal Protein Resource (UniProt) 2009 , 2008, Nucleic Acids Res..
[8] W. Pichler,et al. Degeneracy and additional alloreactivity of drug-specific human αβ+ T cell clones , 2001 .
[9] Yi Wang,et al. In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. , 2006, Toxicology letters.
[10] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[11] Robert A Hegele,et al. Genetic determinants of statin intolerance , 2007, Lipids in Health and Disease.
[12] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Yu Zong Chen,et al. Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.
[14] Todd J. A. Ewing,et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..
[15] D G Myszka,et al. High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. , 2001, Analytical biochemistry.
[16] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..
[17] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[18] C. L. Chepanoske,et al. Ampicillin/penicillin‐binding protein interactions as a model drug‐target system to optimize affinity pull‐down and mass spectrometric strategies for target and pathway identification , 2005, Proteomics.
[19] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[20] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[21] Russell A. Wilke,et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2007, Nature Reviews Drug Discovery.
[22] John A. Baron,et al. Drs. Bresalier and Baron respond [3] , 2006 .
[23] Ying Sun,et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir , 2007, Cell Research.
[24] R. Rando,et al. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. , 1997, Biochemistry.
[25] W. Pichler,et al. Modes of presentation of chemical neoantigens to the immune system. , 2002, Toxicology.
[26] Stephen A. Cammer. SChiSM2: creating interactive web page annotations of molecular structure models using Jmol , 2007, Bioinform..
[27] W. Pichler,et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. , 1997, The Journal of clinical investigation.
[28] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[29] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[30] A. Need,et al. Priorities and standards in pharmacogenetic research , 2005, Nature Genetics.